Bispecific Antibody Market
完整報告名稱與涵蓋範圍
Bispecific Antibody Market Size, Share & Trends Analysis Report, By Mechanism of Action (T Cell Engagers, Dual Immune Checkpoint Targeting, Dual Signaling Pathway Targeting, Factor Mimetics and Other Mechanisms), By Indication (Hematological Malignancies, Solid Tumors, Hemophilia A, Ophthalmic Diseases), By Distribution Channel, By Region, and Segment Forecasts, 2026-2035
報告摘要
Bispecific antibodies are engineered molecules that bind two distinct targets simultaneously, enabling mechanisms unavailable to conventional monoclonals: redirecting T cells onto tumor antigens, bridging clotting factors in hemophilia, blocking two angiogenic ligands in retinal disease, or co-targeting checkpoint and growth pathways in solid tumors. This report covers approved products and the commercial infrastructure around them, with pipeline analysis informing the forecast outlook.
Commercial momentum has broadened decisively beyond hematology. CD3-based T cell engagers against CD20, BCMA, and GPRC5D have established durable franchises in lymphoma and multiple myeloma, and engagers addressing DLL3 have carried the modality into small cell lung cancer. PD-1-based dual-targeting molecules emerging from Chinese developers have produced head-to-head data challenging established checkpoint therapy, triggering some of the largest licensing transactions in the industry and validating bispecifics as a successor architecture in solid tumors. Structural enablers include subcutaneous reformulation and step-up dosing protocols that tame cytokine release syndrome, allowing administration to shift from academic centers toward community oncology, which directly widens the treatable population.
North America contributes the largest revenue owing to rapid adoption of myeloma and lymphoma engagers, Europe follows through health-technology-assessment-driven uptake, and Asia Pacific gains significance as both a market and a discovery engine, particularly China. The landscape couples large-cap innovators with platform biotechs supplying engineering formats through partnerships.
The InsightAce study provides revenue forecasts in US$ across mechanism, indication, distribution channel, and regional segments for 2026-2035, plus segment trends, competitive landscape analysis, and company profiling.
授權報價
| Single User | $4,500 USD |
| Enterprise / Global Site Licence | $9,500 USD |
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Bispecific Antibody Market Snapshot
Chapter 4. Global Bispecific Antibody Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Market Drivers
4.3. Market Challenges
4.4. Emerging Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis - Porter's Five Forces Analysis
4.7. Competitive Landscape and Market Positioning
4.8. Market Opportunity Analysis
Chapter 5. Market Segmentation 1: By Mechanism of Action Estimates & Trend Analysis
5.1. Mechanism of Action & Market Share, 2026 & 2035
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Mechanism of Action:
5.2.1. T Cell Engagers
5.2.2. Dual Immune Checkpoint Targeting
5.2.3. Dual Signaling Pathway Targeting
5.2.4. Factor Mimetics and Other Mechanisms
Chapter 6. Market Segmentation 2: By Indication Estimates & Trend Analysis
6.1. Indication & Market Share, 2026 & 2035
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Indication:
6.2.1. Hematological Malignancies
6.2.2. Solid Tumors
6.2.3. Hemophilia A
6.2.4. Ophthalmic Diseases
6.2.5. Other Indications
Chapter 7. Market Segmentation 3: By Distribution Channel Estimates & Trend Analysis
7.1. Distribution Channel & Market Share, 2026 & 2035
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Distribution Channel:
7.2.1. Hospital Pharmacies
7.2.2. Specialty Pharmacies
7.2.3. Other Channels
Chapter 8. Bispecific Antibody Market: Regional Estimates & Trend Analysis
8.1. North America
8.1.1. United States
8.1.2. Canada
8.2. Europe
8.2.1. Germany
8.2.2. United Kingdom
8.2.3. France
8.2.4. Italy
8.2.5. Spain
8.2.6. Rest of Europe
8.3. Asia Pacific
8.3.1. China
8.3.2. Japan
8.3.3. India
8.3.4. South Korea
8.3.5. Australia
8.3.6. Southeast Asia
8.3.7. Rest of Asia Pacific
8.4. Latin America
8.4.1. Brazil
8.4.2. Mexico
8.4.3. Rest of Latin America
8.5. Middle East & Africa
8.5.1. GCC Countries
8.5.2. South Africa
8.5.3. Rest of Middle East & Africa
Chapter 9. Competitive Landscape
9.1. Company Market Positioning Analysis
9.2. Strategic Developments (Partnerships, Expansions, Product Launches, M&A)
Chapter 10. Company Profiles
10.1. Amgen
10.2. F. Hoffmann-La Roche
10.3. Johnson & Johnson
10.4. Pfizer
10.5. AbbVie
10.6. Genmab
10.7. Regeneron Pharmaceuticals
10.8. Akeso
10.9. Merus
10.10. Zymeworks
10.11. MacroGenics
10.12. Xencor
10.13. Immunocore
10.14. Summit Therapeutics
10.15. BioNTech
圖表清單 List of Tables & Figures
Table 1. Global Bispecific Antibody Market Revenue Forecast by Mechanism of Action, 2026-2035 (US$ Mn)
Figure 1. Global Bispecific Antibody Market Segmentation Overview
Table 2. Global Bispecific Antibody Market Revenue Forecast by Indication, 2026-2035 (US$ Mn)
Figure 2. Global Bispecific Antibody Market Share by Mechanism of Action, 2026 & 2035
Table 3. Global Bispecific Antibody Market Revenue Forecast by Distribution Channel, 2026-2035 (US$ Mn)
Figure 3. T Cell Engager Franchise Expansion Across Hematological Malignancies
Table 4. North America Bispecific Antibody Market Revenue by Country, 2026-2035 (US$ Mn)
Figure 4. Global Bispecific Antibody Market Share by Indication, 2026 & 2035
Table 5. Europe Bispecific Antibody Market Revenue by Country, 2026-2035 (US$ Mn)
Figure 5. Solid Tumor Bispecific Pipeline Landscape by Development Phase
Table 6. Asia Pacific Bispecific Antibody Market Revenue by Country, 2026-2035 (US$ Mn)
Figure 6. Asia Pacific Bispecific Antibody Growth Opportunity Analysis
Table 7. Latin America Bispecific Antibody Market Revenue by Country, 2026-2035 (US$ Mn)
Figure 7. Community Oncology Administration Shift and Subcutaneous Reformulation Outlook
Table 8. Middle East & Africa Bispecific Antibody Market Revenue by Country, 2026-2035 (US$ Mn)
Figure 8. Competitive Positioning of Key Bispecific Antibody Participants
提及公司
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們